INTRA-CELLULAR THERAPIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.56 USD | -2.15% |
|
-6.80% | -8.46% |
| May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
| May. 07 | Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 663M | Sales 2025 * | 924M | Capitalization | 7.07B |
|---|---|---|---|---|---|
| Net income 2024 * | -56M | Net income 2025 * | 91M | EV / Sales 2024 * | 9.35 x |
| Net cash position 2024 * | 872M | Net cash position 2025 * | 926M | EV / Sales 2025 * | 6.65 x |
| P/E ratio 2024 * |
-116
x | P/E ratio 2025 * |
69.8
x | Employees | 610 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Intra-Cellular Therapies, Inc.
More recommendations
More press releases
| 1 day | -2.15% | ||
| 1 week | -6.80% | ||
| Current month | -8.70% | ||
| 1 month | -4.46% | ||
| 3 months | -9.91% | ||
| 6 months | +22.50% | ||
| Current year | -8.46% |
1 week
65.45
71.64
1 month
64.1684.89
Current year
62.7884.89
1 year
45.5084.89
3 years
28.4084.89
5 years
6.7584.89
10 years
6.7584.89
| Managers | Title | Age | Since |
|---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 13-08-28 |
| Director of Finance/CFO | 67 | 13-08-28 | |
Michael Halstead
PSD | President | 51 | 14-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 14-01-07 |
Joel Marcus
BRD | Director/Board Member | 76 | 13-08-28 |
| Director/Board Member | 67 | 14-01-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.14% | 0 M€ | -5.02% | ||
| 0.45% | 0 M€ | 0.00% | - | |
| 0.40% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 67 | -5.91% | 994,208 |
| 24-05-07 | 71.21 | +0.28% | 1,128,033 |
| 24-05-06 | 71.01 | +3.21% | 750,134 |
| 24-05-03 | 68.8 | -2.19% | 909,098 |
| 24-05-02 | 70.34 | -3.29% | 1,233,787 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Companyâs product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
67
USD
Average target price
90.6
USD
Spread / Average Target
+35.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.46% | 7.07B | |
| -3.35% | 88.91B | |
| +2.76% | 41.25B | |
| -13.92% | 31.99B | |
| +50.51% | 24.73B | |
| -15.25% | 15.54B | |
| -39.93% | 12.07B | |
| -9.08% | 12.05B | |
| -14.80% | 12.02B | |
| +6.22% | 8.84B |
- Stock Market
- Equities
- ITCI Stock